|

Press Release: Atlantic Research Group Opens Two New Global Offices

Locations in Switzerland and Australia Next Steps in Controlled Growth Plan

CHARLOTTESVILLE, Va., STEINHAUSEN, Switzerland, and SYDNEY, Dec. 8, 2020 — Atlantic Research Group (ARG), a full-service global contract research organization (CRO), has opened new offices in Switzerland and Australia. The locations in Steinhausen and Sydney strengthen ARG’s global operations and continue the planned evolution of the organization.

ARG, founded in 2004, is an industry leader in clinical trial management in oncology, immunology, rare and neurodegenerative diseases.

With existing offices in London, Amsterdam and Warsaw, ARG continues to invest into Europe with the location in Steinhausen, in the canton of Zug, the center of Switzerland’s biotech industry. ARG significantly bolsters its footprint in Europe and enhances its capability to better serve small to mid-sized pharmaceutical companies.

“We are wholly committed to Europe,” stated Ignazio Di Giovanna, Vice-President of Europe. “From ARG’s legal representation services in a post-Brexit mainland to having additional access to patients and sites, we see opportunities in Switzerland to help our Sponsors. This office is part of our controlled growth plan here in Europe and around the world.”

ARG’s location in Sydney bolsters the organization’s global reach and versatility, according to Lyle Camblos, President and cofounder. “We are excited by the addition of Australia. This gives us a competitive edge in an emerging market and provides a major benefit to our customers.”

Mr. Camblos added: “We expanded in 2018 and 2019 and were determined to move forward with our plans in 2020, despite clear and serious challenges. To add offices in another country in Europe and in another continent at this time allows us to continue executing long-term strategies and goals.”

About ARG:

ARG is an oncology, immunology, rare and neurodegenerative disease-focused contract research organization that provides comprehensive clinical program development services ranging from pre-launch consulting to commercialization, achieving over 50 market authorizations. Founded in 2004 with the vision that every project should be highly individualized, ARG has experienced consistent growth across the globe, expanding our reach to include drug and device strategic consulting, clinical trial management services, and clinical data and analytic solutions. ARG uses first-in-class technology platforms along with relationship-driven flexibility to optimize clinical studies because we believe everyone deserves to be well.

Please download the release here.